IP6K3: A Promising Drug Target / Biomarker (G117283)

Target Name: IP6K3

NCBI ID: G117283

IP6K3

IP6K3: A Promising Drug Target / Biomarker

IP6K3 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the cell signaling pathway known as the TGF-β pathway, which plays a crucial role in cell growth, differentiation, and survival. The TGF-β pathway is involved in the development and maintenance of tissues, including neural networks and organs, and is often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, IP6K3 has potential as a drug target or biomarker.

Drug Target Potential

IP6K3 is a good candidate for a drug target because of its unique structure and the signaling pathway it is involved in. The IP6K3 protein has a unique farnesylated cysteine residue, which is a common structural feature in proteins involved in cell signaling pathways. This residue is involved in the formation of the protein-protein interaction network that is critical for the regulation of the TGF-β pathway. Therefore, inhibiting IP6K3 could lead to a reduction in the activity of the TGF-β pathway, which could potentially lead to therapeutic effects in diseases associated with this pathway.

Biomarker Potential

IP6K3 is also a potential biomarker for some diseases. The TGF-β pathway is involved in the development and maintenance of many tissues, including neural networks and organs, and is often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, IP6K3 could be used as a biomarker to diagnose and monitor these diseases. For example, IP6K3 could be used as a diagnostic marker for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, IP6K3 could be used as a biomarker for monitoring the effectiveness of anti-inflammatory treatments in diseases such as rheumatoid arthritis and inflammatory bowel disease.

In conclusion, IP6K3 is a protein that is expressed in various tissues of the body and is involved in the TGF-β pathway. It has potential as a drug target or biomarker due to its unique structure and the signaling pathway it is involved in. Further research is needed to fully understand the potential of IP6K3 as a drug target or biomarker.

Protein Name: Inositol Hexakisphosphate Kinase 3

Functions: Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). Converts 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4

The "IP6K3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IP6K3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets